A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib.

Trial Profile

A Phase 2 Study of XL820 in Subjects With Advanced Gastrointestinal Stromal Tumors Resistant to or Intolerant of Imatinib and/or Sunitinib.

Completed
Phase of Trial: Phase II

Latest Information Update: 13 Aug 2012

At a glance

  • Drugs XL 820 (Primary)
  • Indications Gastrointestinal stromal tumours
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Aug 2012 Actual end date changed from 1 Mar 2009 to 1 May 2009 as reported by ClinicalTrials.gov.
    • 09 Aug 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Oct 2008 Interim results presented at the 20th EORTC-NCI-AACR Symposium 2008.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top